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The unravelling of the complex 
pattern of tyrosinase inhibition
Batel Deri1,*, Margarita Kanteev1,*, Mor Goldfeder1, Daniel Lecina2, Victor Guallar2,3, 
Noam Adir4 & Ayelet Fishman1
Tyrosinases are responsible for melanin formation in all life domains. Tyrosinase inhibitors are used 
for the prevention of severe skin diseases, in skin-whitening creams and to avoid fruit browning, 
however continued use of many such inhibitors is considered unsafe. In this study we provide conclusive 
evidence of the inhibition mechanism of two well studied tyrosinase inhibitors, KA (kojic acid) and 
HQ (hydroquinone), which are extensively used in hyperpigmentation treatment. KA is reported in 
the literature with contradicting inhibition mechanisms, while HQ is described as both a tyrosinase 
inhibitor and a substrate. By visualization of KA and HQ in the active site of TyrBm crystals, together 
with molecular modeling, binding constant analysis and kinetic experiments, we have elucidated their 
mechanisms of inhibition, which was ambiguous for both inhibitors. We confirm that while KA acts as a 
mixed inhibitor, HQ can act both as a TyrBm substrate and as an inhibitor.
Tyrosinases belong to the type 3 copper-containing protein family together with hemocynanins that serve as oxy-
gen carriers1,2, and catechol oxidases that are strict diphenolases3,4. The two copper ions in the conserved active 
site, CuA and CuB, are coordinated by six histidine residues5–7. Tyrosinases hydroxylate monophenols to form 
ortho-diphenols (monophenolase activity) and subsequently oxidize the o-diphenols to o-quinones (diphenolase 
activity). Melanin is formed rapidly by the spontaneous polymerization of the quinones5,8. Monophenols can 
react only with the oxy state of tyrosinase, which represents about 15% of the enzyme molecules in solution9. In 
the presence of o-diphenols such as L-dopa (L-3,4-dihydroxyphenylalanine), both the oxy and met forms react 
enabling the production of o-quinones4,9.
Disorder in melanin formation has been found to cause a variety of skin diseases in humans such as hyperpig-
mentation, lentigo, vitiligo and skin cancer10. Furthermore, appearance of brown pigments in fruits and vegeta-
bles due to tyrosinase activity is a leading cause for postharvest losses9. Therefore, tyrosinase inhibitors are highly 
warranted by the pharmaceutical, cosmetics and food industries11–15.
Kojic acid (KA), a fungal metabolite, is the most widely used skin-whitening agent with possible side effects 
being dermatitis, sensitization and erythema9,16. Animal experiments suggested possible tumor promotion and 
weak carcinogenicity, and thus concentrations of 1% are recommended for safe human use17. Numerous contra-
dicting mechanisms are described in the literature for KA as either a competitive or mixed inhibitor for mush-
room tyrosinase18–20, possibly by chelating copper in the active site18,20–22. Previously, KA was found bound at the 
entrance to the active site of TyrBm (tyrosinase from Bacillus megaterium), suggesting one significant intermedi-
ate binding site. However, the full mechanism of KA inhibition still remains unclear22.
Hydroquinone (HQ), another well-studied whitening agent, has been used clinically in leading cosmetic 
hyperpigmentation treatment23, however, it was also found to cause serious problems by generating reactive oxy-
gen species leading to oxidative damage of lipids and permanent loss of melanocytes. Subsequently, HQ has 
been banned for the general use by the European Committee and can be prescribed by dermatologists only13,16. 
Previous studies suggested that HQ is a competitive inhibitor of tyrosinase24,25, while others demonstrated the 
potency of HQ as a tyrosinase substrate26,27. Garcia-Canovas and co-workers suggested that the enzymatic activity 
is not evident since HQ is not able to transform met-tyrosinase to the oxy-form26, and that the transformation 
may be substantial by addition of an o-diphenol or H2O226,28. However, to date, no structural data is available in 
order to elucidate the orientation of HQ in the active site of tyrosinase.
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Most mechanistic studies on tyrosinase inhibitors use KA or HQ as the comparative benchmark compound. 
Therefore, in depth analysis of their mechanism and inhibition mode are crucial for further development of 
potent inhibitors.
In this study, we elucidate the inhibition mechanism of these inhibitors by crystal structure determination of 
TyrBm with bound KA and HQ in the active site, along with biochemical characterizations, binding constants 
determination and molecular modeling.
Results
Inhibition mode of TyrBm activity. The most widely used and effective tyrosinase inhibitors, HQ and 
KA9,29, were tested for their inhibitory effect on TyrBm. Overall, our results clearly show that KA and HQ have 
different inhibition modes on TyrBm monophenolase (L-tyrosine) and diphenolase (L-dopa) activities. While 
KA displays a mixed inhibition mode on both activities (Fig. 1 and Table 1), HQ is a competitive inhibitor of 
monophenols, and shows no inhibition of diphenols (Fig. 2 and Table 1), in contrast to previous reports that define 
HQ as a competitive inhibitor for both activities24,25. Our kinetic study showed no inhibition by HQ in the pres-
ence of L-dopa since with rising concentrations of HQ, Km values decreased (Fig. 2b and Supplementary Fig. S1a).
The IC50 values representing inhibitor concentrations in which TyrBm activity was reduced by 50% were 
obtained from dose-response curves (Supplementary Fig. S2). The IC50 values for KA and HQ on the monophe-
nol were 26.8 and 32.0 μ M respectively, while the IC50 value for KA on the diphenol was 52 μ M (Table 1). Similar 
results were obtained in previous reports for mushroom tyrosinase, with values for KA inhibition on monophe-
nols and diphenols of 5.7 and 30.1 μ M, respectively30,31, and the value for HQ inhibition on monophenols of 
33.5 μ M32. Since we observed that HQ does not inhibit tyrosinase in the presence of L-dopa, the value of IC50 was 
not determined. García-Canovas and co-workers suggested that HQ is a tyrosinase substrate and not an inhib-
itor although activity is not evident under conventional conditions since HQ cannot transform met-tyrosinase 
into oxy-tyrosinase26. However, in the presence of an o-diphenol (e.g. L-dopa) or H2O2, oxy-tyrosinase is gen-
erated and HQ becomes a substrate which is hydroxylated to 2-hydroxyhydroquinone and subsequently to 
2-hydroxy-p-benzoquinone (HPB) that can be measured spectrophotometrically26. Our spectrophotomet-
ric measurements confirm their results, since with the addition of H2O2 or L-dopa, product formation by 
TyrBm increased in the presence of HQ (Supplementary Fig. S1). Furthermore, the same trend was observed 
Figure 1. Lineweaver–Burk plots for the inhibition of TyrBm by KA. (a) L-tyrosine (0.03–1.4 mM) in the 
presence of KA concentrations (mM): (a ● ) 0, (b× ) 0.025, (c ▲ ) 0.05, (d ♦ ) 0.075, (e ■ ) 0.1 and (b) L-dopa (0.15–
2.0 mM) in the presence of KA concentrations (mM): (a ● ) 0, (b× ) 0.025, (c ▲ ) 0.04, (d ♦ ) 0.05, (e ■ ) 0.075, (f -) 









L-tyrosine 0.04 ± 0.007 9.7 ± 0.4 5.7 26.8 ± 0.8 1.1 ± 0. 3 61 ± 20 mixed
L-dopa 0.18 ± 0.03 34 ± 1 20.1 52± 3 3.5 ± 0. 6 150 ± 12 mixed
HQ L-tyrosine 0.07 ± 0.01 9.0 ± 0.5 5.3 32 ± 2 40 ± 10 — competitive
Table 1.  Kinetic and inhibition constants of TyrBm by KA and HQ. Data was extracted from Figs 1, 2 and 
Supplementary Fig. S1. Each value represents the mean ± SD of five independent experiments.
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by direct measurement of TyrBm activity through recording of the oxygen consumption during the reaction 
(Supplementary Fig. S3). The activity of TyrBm in the presence of L-dopa and HQ was 8% higher than with 
L-dopa alone for oxygen consumption measurements, and 17% higher as determined by absorbance readings.
In addition, when an activity test was performed for several hours with HQ as a sole substrate in comparison 
to a control without enzyme, low activity was visually observed, even without the addition of H2O2 or L-dopa, and 
a light brown color was detected after 3 hours of incubation (the control remained colorless). Moreover, the low 
inhibitory effect of HQ was also evident in another kinetic study with mushroom tyrosinase that exhibited an IC50 
value 80-fold higher when L-dopa was used, in comparison to L-tyrosine24. Since HQ requires a reducing agent in 
order to become a TyrBm substrate, the kinetic parameters of the monophenolase activity were determined in the 
presence of H2O2. The Km and Vmax values were 0.27 mM and 19 μ mole min−1 mg−1, respectively, which are similar 
to the kinetic parameters of L-dopa (Table 2). A similar Km value of 0.25 mM was reported by García-Canovas and 
co-workers for Agaricus bisporus tyrosinase26.
Effects of KA and HQ on the kinetic parameters of TyrBm. The kinetic constants of TyrBm monophe-
nolase and diphenolase activities were determined for L-tyrosine and L-dopa (Table 2). The values obtained in 
the presence of KA and HQ were calculated from Lineweaver–Burk plots (Figs 1 and 2; Table 1). With rising con-
centrations of KA, the Km values of the monophenolase activity increased and the Vmax values decreased, an indi-
cation of a mixed mode of inhibition, with an inhibition constant KI of 1.1 μ M and KIS of 61 μ M. The apparent Km 
and Vmax were 0.04 mM and 9.7 μ mole min−1 mg−1, respectively (Table 1). When increasing concentrations of KA 
were added in the presence of L-dopa as the substrate, a similar mode of mixed inhibition was observed, with KI 
of 3.5 μ M and KIS of 150 μ M, similar to previous studies that reported KI values of 3.4, 5 and 4.7 μ M for mushroom 
tyrosinase18,19,33. The apparent Km and Vmax of the diphenolase reaction were 0.18 mM and 34 μ mole min−1 mg−1, 
respectively (Table 1). The mixed inhibition mode implies that KA binding is not limited to the active site. In a 
previous study we have already experimentally demonstrated that a peripheral KA binding site exists in TyrBm22.
Increasing concentrations of HQ in the presence of L-tyrosine, resulted in an increase in the Km value while 
the Vmax remained constant, an indication of a competitive inhibition mode on the monophenolase activity, with 
a KI of 40 μ M and apparent Km and Vmax values of 0.07 mM and 9.0 μ mole min−1 mg−1, respectively (Fig. 2a and 
Table 1). A similar inhibition mechanism was also reported by Chawla et al., with KI of 83 μ M for mushroom 
tyrosinase25.
Figure 2. Lineweaver–Burk plots for the inhibition of TyrBm by HQ. (a) L-tyrosine (0.03–1.4 mM) in the 
presence of HQ concentrations (mM): (a ● ) 0, (b× ) 0.025, (c ▲ ) 0.075, (d ♦ ) 0.5 and (b) L-dopa (0.15–2.0 mM) 
in the presence of HQ concentrations (mM): (a ■ ) 0, (b ● ) 0.025, (c ▲ ) 0.05, (d× ) 0.075, (e ♦ ) 0.1. All 
measurements were performed in heptaplicates.
Substrate Km (mM) Vmax (μmole min−1 mg−1) kcat (s−1) kcat/Km (s−1 mM−1)
L-tyrosine 0.082 ± 0.006 3.62 ± 0.06 2.1 25.6
L-dopa 0.24 ± 0.02 30.3 ± 0.6 17.8 74.2
HQ 0.27 ± 0.05 19 ± 1 11.3 41.9
Table 2.  Kinetic constants of TyrBm on its natural substrates and HQ. Data was extracted from Figs 1, 2 and 
Supplementary Fig. S1. Each value represents the mean ± SD of five independent experiments.
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Binding affinity of L-tyrosine vs. inhibitors. In order to obtain a clearer understanding of the fashion 
by which substrates and inhibitors bind to tyrosinase, we have determined dissociation constants (KD) between 
TyrBm and its substrates or inhibitors using MicroScale Thermophoresis34. Surprisingly, such KD values had not 
been previously measured. These experiments were performed by titrating fluorescently-labeled TyrBm with 
increasing concentrations of KA, HQ or L-tyrosine as the unlabeled ligands. According to the thermophoretic data 
points obtained with increasing concentrations of the ligands, the dissociation constants were evaluated. The KD 
values of the TyrBm-KA, TyrBm-HQ and TyrBm-L-tyrosine interactions were determined as 377, 9 and 0.1 μ M, 
respectively (Table 3 and Supplementary Fig. S4). According to these results, L-tyrosine, the natural substrate, 
showed the highest affinity to TyrBm in comparison with KA and HQ. While HQ showed a dissociation constant 
90-fold higher than L-tyrosine, KA exhibited a value of nearly 4000-fold higher than the natural substrate.
Structure of TyrBm with KA in the active site. In addition to the peripheral binding site of KA (PDB 
3NQ1), we have recently determined the structures of TyrBm with L-tyrosine, L-dopa and the substrate analog 
p-tyrosol35, all found within the active site. We present here the crystal structure of TyrBm with KA bound in the 
active site at 2.6 Å resolution (Fig. 3, Supplementary Fig. S5 and Table 4). The possible movement of KA within the 
active site can be envisioned from Fig. 3a in which KA is shown in two positions: the peripheral site we reported 
earlier22, and in the active site. At the entrance to the active site, KA is stabilized by interactions with Phe197, 
Pro201, Asn205, and Arg209 (Fig. 3b)22. In the active site, KA is stabilized by π -π interactions with His208 that 
coordinates CuB, similar to tyrosinase substrates (Fig. 3c), as presented by Goldfeder et al. and suggested in other 
studies35–37. The hydroxyl group of KA is oriented towards CuA with a distance of 3.3 Å, while the distance of the 
carbonyl group to CuA is 5.5 Å. These results are supported by a recent docking study of Lima et al.18, and contra-
dict a previously proposed inhibition mechanism of KA by copper chelation20–22.
In silico simulations of KA and HQ in the active site. TyrBm structure with KA at the entrance to the 
active site was used as an initial model to run an extensive non-biased ligand migration simulations with PELE 
(Protein Energy Landscape Exploration) in a constrained sphere of 20 Å (from the initial ligand center of mass)38. 
By means of 128 processors and 24 hours, ~200,000 different ligand conformations were obtained that allowed 
to evaluate the absolute binding free energy (∆ G) by Markov State Models (MSM) analysis39. Briefly, MSM first 
involves clustering all conformations (a total number of 100 clusters were used) in metastable states and building 
the transition matrix between them. The obtained clusters overlap mostly with the two positions of KA, at the 
peripheral site and in the active site (Fig. 4). Integration of these cluster centers (with respect to the bulk solvent) 
allowed determining the binding free energy for the active site structure of − 5.5 kcal/mol, whereas the surface 
bound complex was only of − 1.4 kcal/mol. Therefore, the transition from the surface bound complex to the active 
site is exothermic and likely to occur.
An analogous simulation was also performed for HQ. In contrast to KA, HQ showed a significant larger 
mobility in the active site, where multiple orientations are frequently visited. This is clearly seen when ana-
lyzing the metastable states (after MSM clustering) accessible within 1 kcal/mol from the best-bound minima 
(Supplementary Fig. S6). While KA presents mainly two orientations (that occupy similar volume), HQ adopts 
multiple orientations exploring a larger area of the active site. Interestingly, for HQ we found structures (within 
the lowest 1 kcal/mol) involving the peripheral site, which for KA is about 4.1 kcal/mol above the best-bound 
minima (Fig. 4).
Structure of TyrBm with HQ in the active site. The kinetic measurements with HQ indicated that it is 
a poor substrate of TyrBm under natural conditions, and a good substrate in conditions favoring oxy-tyrosinase. 
In order to trap HQ in the active site of TyrBm, mature crystals were soaked with zinc instead of copper ions 
to prevent enzymatic activity22,35,40. We have obtained two different structures of TyrBm with HQ bound in the 
active site (Supplementary Figs S7 and S8) at 2.2 Å resolution (Table 4). The HQ hydroxyl group is oriented 
towards ZnA, and its benzyl ring is stabilized through hydrophobic interactions with His208, similar to tyrosine 
substrates (Fig. 5a)35. HQ was observed to bind in three different orientations in total in the active site of TyrBm 
(orientations 1, 2 and 3) (Fig. 5, Supplementary Figs S7 and S8). It seems that HQ binding is rather flexible in the 
active site, agreeing with the in silico simulations shown above, and does not have one specific orientation in con-
trast to L-tyrosine and L-dopa (Fig. 5)35. In orientation 1, a polar interaction between HQ and Asn205 is observed 
(Fig. 5b). In orientation 2, the HQ molecule is oriented similarly to tyrosinase substrates (and KA) in the active 
site, supporting our kinetic experiments showing that HQ can act as a TyrBm substrate (Fig. 5a). In addition, 
when TyrBm crystals were soaked with copper and HQ for 16 hours, the crystals turned brown, in comparison to 
crystals that were soaked with zinc that did not show a change in color (data not shown). Brown TyrBm crystals 
indicate on substrate oxidation as was previously shown by Sendovski et al. and provide additional confirmation 
on the role of HQ as a substrate of TyrBm22.
TyrBm ligand KD (μM)
KA 377 ± 4
HQ 9 ± 1
L-tyrosine 0.10 ± 0.03
Table 3.  Dissociation constants of TyrBm-ligand complexes. Each value represents the mean ± SD.
www.nature.com/scientificreports/
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Discussion
Disorders in melanin formation have been linked to various skin diseases in humans such as hyperpigmentation 
and skin cancer. KA and HQ, are frequently used as inhibitors of tyrosinase, and have been used as skin-whitening 
agents in leading cosmetic hyperpigmentation treatment9,13,14,16. Over the past few years, numerous docking 
studies and molecular dynamic simulations were performed in an attempt to elucidate the binding modes of 
Figure 3. Structures of KA bound to TyrBm. (a) KA is observed inside the active site (purple) and at the 
entrance to the active site (green) (3NQ1). Copper ions are presented as brown spheres. (b) KA at the entrance 
to the active site (green) (3NQ1) is stabilized by second shell residues (light brown sticks). (c) Superposition 
with TyrBm structures contain KA (purple) and L-dopa (orange, 4P6S) oriented through hydrophobic 
interactions with His208. All the structures presented in this work were generated using PyMOL.
Structure name (PDB code) TyrBm:KA (5I38) TyrBm:HQA (5I3A) TyrBm:HQB (5I3B)
Data collection 
 Space group P212121 P212121 P212121
Cell dimensions
 a, b, c (Å) 70.24, 74.97, 121.70 69.62, 74.38, 120.78 69.62, 74.42, 119.69
 α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90
 Resolution (Å) 51.26–2.5 35.54–2.2 33.43–2.2
 Rmerge*,† 0.12(0.25) 0.082(0.387) 0.08(0.326)
 I/σI* 9.7(5.9) 18.2(6.2) 15.4(5.8)
 Completeness* 90.4(99.3) 99.9(100) 99.8(99.9)
 Redundancy* 6.2(5.8) 12.6(13.1) 6.6(6.9)
Refinement
 Resolution (Å) 51.26–2.5 35.54–2.2 33.43–2.2
 No. of reflections 127,679 558,159 214,516
 Rwork/Rfree‡ 20.81/23.77 20.11/22.72 18.84/21.69
No. of atoms
 Protein 4,687 4,697 4,696
 Ligand/ion 36 33 33
 Water 84 226 272
B-factors (Å) 
 Protein 32.05 35.02 32.75
 Ligand/ion 33.51 39.86 29.39
 Water 30.74 37.73 35.42
Root mean square deviations
 Bond length (Å) 0.004 0.007 0.006
 Bond angle (°) 0.59 0.88 0.80
Table 4.  Data collection and refinement statistics. *Values in parentheses are for the last shell. †Rmerge =  
∑ hkl∑ i |Ii(hkl)−〈 I(hkl)〉 |/∑ hkl∑ iIi(hkl), where I is the observed intensity, and < I> is the mean value of I. ‡R/
Rfree = ∑ hkl||Fobs|−|Fcalc||/∑ hkl|Fobs| where R and Rfree are calculated using the test reflections respectively. The test 
reflections (5%) were held aside and not used during the entire refinement process.
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tyrosinase inhibitors. In this work we demonstrate for the first time the true binding orientations of KA and HQ 
in the active site of TyrBm which explain the biochemical characterization.
Previously, we had determined a crystal structure of TyrBm with KA bound at the entrance to the active site22. 
Here, by modifying our protocol for ligand binding in crystal, we have visualized the structure of TyrBm with 
KA bound in the active site similar to tyrosinase substrates (Fig. 3c). This position of KA might lead to the false 
assumption of competitive inhibition mechanism. However, the two orientations of KA, which are demonstrated 
by crystallography and in silico simulations (Figs 3 and 4), support the mixed inhibition mechanism, which is 
confirmed by our kinetic experiments (Fig. 1 and Table 1).
In contrast to previous studies18–20, in this work we unequivocally display mixed inhibition mode of KA on 
both monophenolase and diphenolase activities and undermine the hypothesis regarding copper chelation by 
KA. Since the KIS value is significantly greater than KI for the oxidation of both L-tyrosine and L-dopa (Table 1), 
KA is able to bind more strongly to the free enzyme than to the enzyme–substrate complex (at the peripheral 
Figure 4. KA’s center of mass cluster analysis along the PELE simulation. Clusters are presented as spheres 
and colors indicate the potential of mean field ∆ G. Absolute standard binding free energies (with volume 
corrections) are shown for the active site and the surface bound minima, along with the ligand crystallographic 
complexes (cyan sticks). The two copper ions are presented as brown spheres.
Figure 5. Structures of HQ bound in the active site of TyrBm. (a) Superposition with TyrBm structures 
contain HQ in orientation 2 (green) and L-tyrosine (blue, 4P6R), which forms a hydrogen bond with Arg209. 
Zinc ions are presented as grey spheres. (b) HQ, in orientation 1 (teal), forms a hydrogen bond with Asn205 His 
residues are in white.
www.nature.com/scientificreports/
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site). We suggest that when KA is bound strongly in the active site, the binding pocket is not accessible to sub-
strate molecules, subsequently TyrBm is not active. However, when KA is oriented at the entrance of the active 
site, it restricts substrate entrance and product efflux, consequently, TyrBm cannot reach its maximum velocity 
(Table 1). Tropolone, another tyrosinase inhibitor that has been studied, was also found at the entrance of the 
active site of mushroom tyrosinase and exhibited mixed inhibition mode similar to KA41,42. It is quite possible, 
that KA may also bind to this site or has a different peripheral binding site yet to be elucidated. Together with the 
fact that KA showed a dissociation constant 3-orders of magnitude higher than L-tyrosine, these findings support 
the existence of a significant intermediate binding site in TyrBm and explains the mechanism of mixed inhibition.
Numerous studies have raised questions regarding the behavior of HQ as a tyrosinase inhibitor26,27, and most 
of them characterized HQ as a competitive inhibitor24,43–45. Our results support this inhibition mode of HQ on 
L-tyrosine (Fig. 2a and Table 1). On the other hand, other studies demonstrated the potency of HQ as a tyrosinase 
substrate26,27. Stratford and co-workers suggested that HQ is neither a substrate nor an inhibitor of tyrosinase27 
while del Mar García-Molina et al. suggested that HQ is a tyrosinase substrate with a poor activity due to the ina-
bility to transform met-tyrosinase to oxy-tyrosinase on its own26. The transformation is achieved by addition of an 
o-diphenol (such as L-dopa) or H2O2, which promotes the activity on HQ26,28. Our results corroborate this argu-
ment, since in the presence of H2O2 or L-dopa, TyrBm was indeed active on HQ as measured by two unrelated 
methods (Fig. 2b and Supplementary Figs S1 and S3). These findings led us to determine the kinetic constants of 
TyrBm with HQ as a substrate, which resulted in a similar Km value for HQ and L-dopa, and a Vmax value higher 
than that of L-tyrosine (Table 2).
Additional conclusive evidence for the action of TyrBm on HQ lies in the formation of brown crystals soaked 
in HQ that indicate on substrate oxidation as was previously shown by Sendovski et al. with L-tyrosine22. We 
assume that small amounts of oxy-TyrBm molecules present in the crystals enabled the activity on HQ within 
16 hours that resulted in brown pigmentation9.
In order to elucidate the inhibition mechanism of HQ, we solved two crystal structures of TyrBm with HQ in 
the active site. It was discovered that HQ is bound less strongly than L-tyrosine (Table 3), and its binding heter-
ogeneity is evident from the several different orientations observed in the active site (Fig. 5 and Supplementary 
Fig. S7). It is presumed that the polar amine and carboxyl groups of L-tyrosine and L-dopa, which are not present 
in HQ, help to stabilize the substrates through polar interactions with Arg209 in a productive mode (Fig. 5a)35. 
In orientation 1, a hydrogen bond between HQ and Asn205 was observed (Fig. 5b). Asn205 was suggested to be 
crucial for tyrosinase activity through the activation of a conserved water molecule35,46. The interaction of Asn205 
with HQ might prevent this activation, and thus inhibit tyrosinase activity18,47,48. Furthermore, in the structures 
of TyrBm with KA at the entrance of the active site this interaction was also found to be important for KA stabi-
lization22. Thus, we propose that the polar bond between Asn205 and the hydroxyl group of HQ indicates on an 
inhibitory effect on TyrBm. In contrast, in orientation 2, HQ is positioned similarly to L-tyrosine in the active 
site (Fig. 5a), supporting the role of HQ as TyrBm substrate. The flexibility of HQ in the active site of TyrBm was 
also demonstrated by our PELE simulations, which provided visualization of the numerous energetically feasible 
orientations of HQ in the active site. Whereas for KA it takes some time and energy to go from the peripheral 
docking site to the inner active site, for HQ there is constant interconversion between the two of them suggesting 
that the pre-docking site is very transient.
It seems that the combination of both the orientation of HQ in the active site and the oxidative state of tyrosi-
nase will define the behavior of HQ.
Methods
Expression, purification and crystallization of tyrosinase from B. megaterium. The gene encod-
ing tyrosinase from Bacillus megaterium (TyrBm) was cloned into Escherichia coli BL21, purified and crystallized 
as previously described49,50.
Tyrosinase inhibition assay. Tyrosinase inhibitory activity was determined spectrophotometrically in 
96-well plates with a final volume of 200 μ l. First, 50 mM PBS buffer pH 7.4 and 0.01 mM CuSO4 were mixed with 
6 μ g ml−1 of purified enzyme. Then, the mixture was incubated at 40 °C for 2 minutes. Finally, various concentra-
tions of inhibitor were mixed with 1.2 mM L-tyrosine or 2 mM L-dopa and were added to the pre-incubated mix-
ture. KA was studied in the range of 0.025–0.1 mM and HQ in the range of 0.025–0.5 mM. The reaction mixture 
was then monitored for L-dopachrome formation (ε = 3600M−1 cm−1) by measuring the absorbance at 475 nm. 
Specific activity was calculated as the ratio of the conversion rate and the total protein content as determined by 
the Bradford analysis method (Bio-Rad, Israel). All measurements were performed in seven replicates. The inhib-
itor concentration necessary for 50% inhibition (IC50) was determined with respect to a control (no inhibitor).
Kinetic analysis of tyrosinase. The mode of inhibition and inhibition parameters, i.e. the Michaelis–
Menten constant (Km), maximal velocity (Vmax), turnover number (kcat) of TyrBm and the inhibition constants 
(KI, KIS) of each inhibitor were determined by Lineweaver–Burk plot analysis using various concentrations of 
L-tyrosine (0.03–1.4 mM) and L-dopa (0.15–2.0 mM) as substrates. The inhibitor concentrations were mentioned 
above. The inhibition kinetics module of Sigma Plot 13.0 software was used (Systat Software, Inc., Richmond, CA, 
USA). All measurements were performed in 5-replicates.
Tyrosinase activity assay on HQ as a substrate. TyrBm activity was determined by measuring the for-
mation of 2-hydroxy-p-benzoquinone (HPB) from HQ, in the presence of H2O2 or L-dopa. TyrBm activity was 
determined as explained in the inhibition assay above with varying concentrations of H2O2, ranging from 0 to 
90 mM, while maintaining the concentration of HQ constant. The formation of HBP was monitored by measuring 
the absorbance at 475 nm26.
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The values of Km, Vmax and kcat of TyrBm in the presence of HQ as a substrate were determined with the follow-
ing conditions: 50 mM PBS buffer pH 7.4, 0.01 mM CuSO4, 6 μ g ml−1 of purified enzyme, various concentrations 
of HQ (0.1–2.0 mM) in the presence of saturating concentration of hydrogen peroxide (100 mM)51.
For further verification of TyrBm activity on HQ, the activity was determined by recording the oxygen con-
sumption in the presence of L-dopa and HQ. Measurements were carried out using a Hansatech Oxygraph+ elec-
trode (Norfolk, UK) in a reaction volume of 1000 μ L. The reaction contained 4 μ g ml−1 of purified TyrBm, 50 mM 
PBS buffer pH 7.4, 0.01 mM CuSO4, 1 mM L-dopa and 0.1 mM HQ.
Dissociation constants using MicroScale Thermophoresis (MST). TyrBm was labeled fluorescently 
with a RED dye (NT-647-NHS) according to the manufacturer’s protocol (NanoTemper Technologies, Munich, 
Germany). Non-bound dye was removed by purification of the enzyme on a Sephadex G-25 column with buffers 
provided in the commercial kit. Then, serial dilutions of unlabeled binding partner samples (inhibitor or sub-
strate) were mixed with 0.377 μ M of dye-labeled TyrBm in 50 mM PBS buffer pH 7.4 and incubated for 5 minutes. 
Approximately 10 μ l of sample was loaded into hydrophilic monolith NT capillaries and the measurement was 
performed in a NanoTemper Monolith NT.015T instrument. The emission of the red fluorescence was recorded at 
a focused location of the capillary. In the same location, a microscopic temperature gradient was created using an 
infrared laser and the fluorescence depletion was measured. According to changes in the fluorescent thermopho-
resis signal and the concentrations of unlabeled inhibitor, the dissociation constant values were determined by the 
NanoTemper analysis software. The unlabeled binding partners tested for KD determination were KA (0–4 mM), 
HQ (0–1 mM) and L-tyrosine (0–2 mM).
Statistical analysis. All experiments were performed in duplicates or triplicates in order to ensure the 
reproducibility of the results. Statistical analysis was performed using Student’s t-test: *P < 0.05 compared with 
the control. Data is summarized as mean ± SD.
Substrate binding in crystals. In order to trap ligands in the active site, mature crystals were soaked over-
night in 1 mM of either CuSO4 or ZnCl2 and subsequently in 10 mM of the appropriate ligand (KA and HQ) 
before crystal freezing.
Data collection and structure determination. X-ray diffraction data was collected at the European 
Synchrotron Radiation Facility, Grenoble, France, at beamlines ID14-4 and ID 29. All data were indexed, inte-
grated, scaled and merged using Mosflm and Scala52. The structures of TyrBm with bound inhibitors were solved 
by molecular replacement using Phaser53 and the coordinates of earlier determined TyrBm structure (PDB code 
4P6R). Refinement was performed using Phenix54 and Refmac555,56, coupled with rounds of manual model 
building, real-space refinement and structure validation performed using COOT57. Data collection, phasing and 
refinement statistics are presented in Table 3.
In silico simulations. Ligand migration sampling with Protein Energy Landscape Energy (PELE). PELE has 
widely been used to study ligand-protein interactions and protein dynamics at a fraction of the cost compared 
to other sampling methods such as molecular dynamics58–60. This algorithm is composed of a perturbation and a 
relaxation stage, and uses a mixture of random moves with protein structure prediction algorithms. The resulting 
structure is accepted or rejected following the Metropolis criterion.
Binding free energy with Markov State Models (MSM). MSM are coarse grain statistical models that allow 
extracting equilibrium properties such as the binding free energy61. In order to build our MSM, we split the 
conformational space using the Voronoi decomposition, clustering the ligand’s center of mass and using the 
cluster centers as seeds. Hence, each microstate will contain all possible ligand, protein and solvent arrangements 
compatible with having the ligand’s center of mass within the cell. In order to study the different metastable min-
ima, microstates are kinetically clustered utilizing Perron Cluster Analysis (PCCA+ ). The absolute binding free 
energy, ∆ G, is obtained integrating the potential of mean force (Gpmf) in the whole bound region39.
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